Stocktoria
Fortress Biotech, Inc. FBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2011-11-17
Fortress Biotech, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M |
| R&D expense | — | — | $106.1M | $134.9M | $128.9M |
| SG&A expense | $96.4M | $87.7M | $91.0M | $113.7M | $86.8M |
| Operating income | -$70.2M | -$110.4M | -$142.3M | -$203.6M | -$188.5M |
| Income tax | -$620,000 | $312,000 | $521,000 | $449,000 | $473,000 |
| Net income | $6.8M | -$46.0M | -$60.6M | -$86.6M | -$64.7M |
| EPS (diluted) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 |
| Operating cash flow | -$65.8M | -$80.2M | -$128.2M | -$179.4M | -$116.5M |
| Free cash flow | — | -$80.2M | -$128.3M | -$182.1M | -$121.1M |
| Cash & equivalents | $79.4M | $57.3M | $80.9M | $178.3M | $305.7M |
| Inventory | $9.6M | $14.4M | $10.2M | $14.2M | $9.9M |
| Total assets | $185.5M | $144.2M | $167.5M | $294.3M | $396.5M |
| Total liabilities | $123.4M | $145.9M | $165.9M | $244.3M | $170.6M |
| Shareholders' equity | $62.2M | $22.7M | $22.5M | $50.0M | $225.9M |
Source: SEC EDGAR filings · CIK 0001429260 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.